Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 3Phase 1/2 3Phase 1 3Phase 3 2Phase 2/3 2

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Leukemia, Myeloid, Acute 24Breast Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Sarcoma 9Myelodysplastic Syndromes 9Stomach Neoplasms 8Multiple Myeloma 7Leukemia, Myelomonocytic, Chronic 7Myeloproliferative Disorders 6Uterine Cervical Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Lung Neoplasms 5Recurrence 4Prostatic Neoplasms 4Neoplasms 4Melanoma 4Leukemia, Monocytic, Acute 4Head and Neck Neoplasms 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Carcinoma, Hepatocellular 4Biliary Tract Neoplasms 4Advanced Solid Tumour 4Stomatitis 3Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neuroendocrine Tumors 3Mucositis 3Leukemia, Myelomonocytic, Acute 3Cholangiocarcinoma 3

Interventions

Bevacizumab 69Sorafenib 66lenvatinib 59durvalumab 38sintilimab 33Nivolumab 32tislelizumab 28atezolizumab 28pembrolizumab 27Oxaliplatin 26tremelimumab 23apatinib 22Fluorouracil 22Radiosurgery 20regorafenib 19camrelizumab 18Doxorubicin 18cabozantinib 16Leucovorin 16Capecitabine 16Radiotherapy 14Folfox protocol 14donafenib 13Gemcitabine 13Cisplatin 12toripalimab 11Erlotinib Hydrochloride 10spartalizumab 8anlotinib 8Neoadjuvant Therapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Hepatocellular × Injections × Clear all
NCT05099848 2026-05-22

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Shandong Cancer Hospital and Institute

Phase 2 Completed
21 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04727307 2025-09-30

AB-LATE02

University Hospital, Montpellier

Phase 2 Recruiting
202 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases

NCT06526338 2025-09-30

Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone

University of Louisville

Phase 2 Recruiting
126 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06558227 2024-12-16

Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡